Investigational drug · Phase 2
EG-70
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "EG-70"
First trial start
2021
Apr 22, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EG-70", any sponsor or status.
Conditions studied
As listed on its trial records.
- Superficial Bladder Cancer
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Non-muscle Invasive Bladder Cancer
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "EG-70" as an intervention, largest first.
enGene, Inc.Industry
NCT04752722 · 350 participants (planned) · Start Apr 22, 2021 · Primary completion Apr 30, 2028
Drug: EG-70 (phase 1); EG-70 (phase 2) Master Protocol and 1 more · For: Superficial Bladder Cancer; Non-muscle Invasive Bladder Cancer With Carcinoma in Situ; Non-muscle Invasive Bladder Cancer
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 102 sites in all
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT00737438 · 22 participants · Start Aug 2008 · Primary completion Feb 2015
Drug: epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan · For: Esophageal Cancer; Gastric Cancer
Sites: Basking Ridge, New Jersey; Commack, New York; New York, New York · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.
Abou Chakra M, Duquesne I, O'Donnell MA · Front Biosci (Landmark Ed) 2026
- Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions.
Pinton P · Cancers (Basel) 2025
- Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation.
Wong CH, Leung DK, Gontero P, et al. · Curr Opin Urol 2025
- Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer.
Gurbani CM, Chong YL, Choo ZW, et al. · Bladder Cancer 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.